SUMMARY -Th e purpose is to report on the safety and effi cacy of Ahmed Glaucoma Valve (AGV, New World Medical, Inc., Rancho Cucamonga, CA, USA) implantation for the management of refractory pediatric glaucoma observed during one-year follow up period. A retrospective chart review was conducted on 10 eyes, all younger than 11 years, with pediatric glaucoma that underwent AGV implantation for medicamentously uncontrolled intraocular pressure (IOP) between 2010 and 2014. Outcome measures were control of IOP below 23 mm Hg (with or without antiglaucoma medications) and changes in visual acuity. Complications were recorded. After AGV implantation, IOP values ranged from 18 mm Hg to 23 mm Hg (except for one eye with postoperative hypotonia due to suprachoroid hemorrhage, where the postoperative IOP value was 4 mm Hg). Th e number of antiglaucoma medications was reduced, i.e. four patients had two medications, one patient had one medication, and the others did not need antiglaucoma medication on the last follow-up visit. One eye had suprachoroid hemorrhage, one eye had long-term persistent uveitic membrane, and two eyes had tube-cornea touch. In conclusion, AGV implantation appears to be a viable option for the management of refractory pediatric glaucoma and shows success in IOP control. However, there was a relatively high complication rate limiting the overall success rate.
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Introduction
Pediatric glaucoma is a potentially blinding disease, which is often refractory to medical treatment. Although traditional surgical procedures for the management of pediatric glaucoma, such as goniotomy, trabeculotomy, and combined trabeculotomy and trabeculectomy have high success rates when performed as initial surgical procedures 1,2 , many of the children with pediatric glaucoma will require other forms of surgical therapy to achieve adequate control of intraocular pressure (IOP). Some of the more refractory secondary pediatric glaucomas, such as those associated with anterior segment dysgenesis, aniridia, Sturge-Weber syndrome, and following congenital cataract surgery, show poor results using these surgical approaches 3, 4 . Glaucoma drainage devices have become popular in the management of these glaucomas. Th e Molteno, Ahmed and Baerveldt implants are currently the most popular implants used in the management of refractory glaucoma.
Th e purpose of this study was to evaluate the efficacy of the Ahmed Glaucoma Valve implant (AGV, New World Medical Inc., Rancho Cucamonga, CA, USA) in pediatric patients with refractory glaucoma related to IOP control, changes in visual acuity, and complications during one-year follow up period.
Subjects and Methods
A retrospective chart review was conducted on 10 eyes in nine consecutive pediatric patients with refractory glaucoma treated with AGV implantation from 2010 to 2014 at the Clinical Department of Ophthalmology, Sestre milosrdnice University Hospital Center, Zagreb, Croatia. Th ere were six boys and four girls, all younger than 11 years. Th e retrospective review of patient charts for this study was approved by the Hospital Ethics Board. All surgeries were performed by the same surgeon (Z.M.), who was also present at all follow up examinations.
Th ere were 4 eyes with secondary aphakic glaucoma, 3 eyes were pseudophakic with uncontrolled IOP, 1 eye had secondary uveitic glaucoma, and 2 eyes had primary congenital glaucoma.
Combined trabeculotomy with trabeculectomy procedure was previously performed in each eye, and trabeculectomy with trabeculotomy at 6 o'clock position was also previously performed in 2 eyes. All study subjects had uncontrolled IOP, which means more than 21 mm Hg despite maximal medical therapy (≥3 topical antiglaucoma medications).
Surgery was performed under general anesthesia in all eyes using the S-3 model (pediatric size of AGV). Th e implant was placed in the superior-temporal quadrant in all eyes except for one eye where it was placed in the supero-nasal quadrant, at a distance of 8-10 mm from the limbus. Th en scleral fl ap was formed to cover the external surface of the tube. Th e tube was inserted into the anterior chamber, after being primed with balanced salt solution, using a 23 gauge needle, parallel to the iris surface, into the ciliary sulcus. Th e tube was fi xed to the sclera using 10-0 nylon suture and conjunctiva was repositioned and sutured.
In the immediate postoperative period, patients received topical atropine combined with topical corticosteroids and antibiotic preparations that were tapered slowly over a 4-week period.
Each patient was reviewed within the week before surgery and daily for the fi rst 5 postoperative days at a minimum. After that, patients were examined 3 to 4 weeks after surgery and at various intervals thereafter until the fi nal visit, with minimum follow up of 1 year.
Intraocular pressure was measured awake using Goldmann applanation tonometer or under general anesthesia when patients were uncooperative for evaluation. Perkins tonometer was only used for examinations under anesthesia.
Complete
Th e following data were extracted from medical records: age, sex, type of glaucoma, visual acuity measurements when available (before and after surgery), details of slit lamp examination or under the operating microscope (before and after surgery), IOP measurement obtained with Perkins or Goldmann applanation tonometry (before and after surgery), optic disk and fundus evaluation, and axial length measurements when available (before and after surgery). Th e number of topical antiglaucoma medications before and after surgery, was also noted in medical records. Details of surgeries performed prior to AGV implantation were noted. Operative details included the model of the implant used, the quadrant in which it was placed, and intraoperative surgical complications, if any. Postoperative details included visual acuity, IOP measurements, number of medications, complications, and additional interventions in the postoperative period. Table 1 summarizes data recorded in the study. Th ere were 4 eyes with secondary aphakic glaucoma, 3 eyes were pseudophakic with uncontrolled IOP, 1 eye had secondary uveitic glaucoma, and 2 eyes had primary congenital glaucoma (1P, 2P). Visual acuity was the same before and at the end of follow up period. IOP values before AGV implantation ranged from 25 mm Hg to 38 mm Hg despite maximal medical therapy. After AGV implantation, IOP values were from 18 mm Hg to 23 mm Hg (except for 1 eye with postoperative hypotonia due to suprachoroid hemorrhage, where the postoperative IOP value was 4 mm Hg). Th e number of antiglaucoma medications was reduced in postoperative period, i.e. four patients had two medications, one patient had one antiglaucoma medication, and the others did not need antiglaucoma medication on the last follow-up visit. Table 1 also shows fi nal outcome where success was defi ned as IOP <21 mm Hg and the success rate was 50%. Figure 1 shows normal postoperative fi nding after AGV implantation.
Results
In our study, only one eye had a fl at anterior chamber and hypotonia secondary to suprachoroid hemorrhage. Th e preoperative IOP in this eye was 37 mm Hg, and postoperative hypotonia was 4 mm Hg (previously mentioned patient) ( Table 1, Fig. 2 ). Th ere were two patients with tube-cornea contact (Table 1 , Fig. 3 ). Th is occurred early in our case series and the rate of tube contact has since been reduced by modifying surgical protocol to place the tube more posteriorly in the anterior chamber. Th e tube contact tended to occur in buphthalmic eyes of very young patients, perhaps because of the reduced scleral rigidity and anterior migration of the anterior chamber tube with postoperative pressure reduction, which allowed shrinkage of the stretched sclera and globe 5 . One patient had uveitic membrane in the early postoperative period, which resolved after two months (Fig. 4) , and one patient had hyphema, which resolved during the fi rst postoperative week (Fig. 5) . 
Discussion
Glaucoma drainage implants are useful when other surgical treatments have a poor prognosis for success, prior conventional surgery fails, or when signifi cant conjunctival scarring precludes fi ltration surgery. Studies of glaucoma drainage implants in pediatric patients report success rate ranging from 56% to 95%, depending on patient age, type of glaucoma, variations in the defi nition of success, and length of follow up [6] [7] [8] [9] [10] . However, complications have been associated with drainage implants in pediatric patients. Reported complications include hypotonia with fl at anterior chamber and choroid detachment, tube-cornea touch and corneal edema, obstructed tube, exposed tube or plate, endophthalmitis, and retinal detachment. Postoperatively, patients often require adjunctive glaucoma medications 5 . In the study, we had one patient with fl at anterior chamber due to suprachoroid hemorrhage and none of the other eyes had shallow or fl at anterior chamber that required reformation during the study. Shallow or fl at anterior chambers can be diffi cult to manage in pediatric patients, and additional anesthesia is often necessary. Also, we had two patients with tube-cornea contact due to postoperative tube migration (typically anteriorly). Other studies report this complication in 26% to 35% of patients [11] [12] [13] . Th is phenomenon is more likely in the elastic infant eye than in the older child or adult 5 . In the present study, there were no other complications.
Th e World Glaucoma Association guidelines for reporting success rates following glaucoma surgical procedures recommend several alternatives for the upper limit (<21 mm Hg, 18 mm Hg, 15 mm Hg and 12 mm Hg), and one for the lower limit (6 mm Hg) 14 . Most reports on the use of AGV in pediatric eyes use an upper limit of 21 mm Hg to 23 mm Hg and lower limit of <5 mm Hg with or without medications to defi ne success, and report success rates of 70% to 94% using these defi nitions 15 . In our series, 50% of the eyes had successful control of IOP at the fi nal visit using these defi nitions. Although these patients required adjunctive glaucoma medications to achieve satisfactory IOP, they had no need for additional surgical intervention during the one-year follow up period.
Our study had the limitations of retrospective design, mixture of preoperative diagnoses, and a relatively small sample size. Collected data were limited to those that were available in medical records.
